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ABSTRACT
Hematopoietic stem cell transplant (HSCT) recipients  should be routinely revaccinated 
after transplantation. We evaluated the difficulties met in the revaccination program and how 
a prospective and tailored follow-up could help to overcome these obstacles. HSCT recipients 
(n=122) were prospectively followed up and categorized into Group 1 (n=72), recipients 
who had already started the revaccination program, and Group 2 (n=50), recipients starting 
their vaccines. Whenever a difficulty was reported, interventions and subsequent evaluations 
were performed. Reported problems were related to patient compliance, HSCT center and/
or vaccination center. Problems related to patient compliance were less frequent than those 
related to HSCT center modifications of previous recommendations, or to errors made by 
the vaccination center. The main gap found was vaccination delays (81.9%). Advisory 
intervention was needed in 64% and 46% of Group 1 and Group 2, respectively (p=0.05), and 
was partially successful in around 70% of the cases. Total resolution was achieved in more 
than 35% in both groups. Improvements are needed in the Brazilian vaccination program for 
HSCT recipients to assure a complete and updated revaccination schedule. HSCT centers 
should assign nurses and transplant infectious disease specialist physicians to organize the 
revaccination schedule and to monitor the program development.
KEYWORDS: Hematopoietic stem cell transplantation. Immunization. Difficulties in 
revaccination.
INTRODUCTION
After hematopoietic stem cell transplantation (HSCT), a temporary state of 
combined immunodeficiency occurs, with gradual recovery of humoral and cellular 
immunity during the early years of transplantation1. The immunodeficiency state 
places the recipient at an increased risk for a variety of pathogens, some of which 
may be prevented by immunization2-4.
Antibody titers to vaccine-preventable diseases, such as tetanus, diphtheria, polio, 
or measles, decrease from one to ten years after HSCT 5-8. Therefore, a revaccination 
program is recommended for both allogeneic and autologous HSCT recipients2,9-11.
The difference between the ideal scenario presented in guidelines and real-
life scenarios is one of the most recognized barriers to the implementation of 
recommended practices12. Brazil has a national immunization program, which 
guarantees full and free access for all population. Through the National Immunization 
Program, the Brazilian Ministry of Health offers a free vaccination program for 
immunocompromised patients managed by the Reference Centers for Special 
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Immunobiologicals (CRIE), spread regionally across 
the country. Despite the excellence of the revaccination 
program, several pitfalls have been observed over the years. 
The present study aimed to demonstrate the pitfalls 
found in the post-HSCT revaccination process, and 
how a prospective and tailored follow-up developed by 
a specialized nurse and a transplant infectious disease 
specialist physician may help to overcome such obstacles.
MATERIAL AND METHODS
The study was conducted at the outpatient facility of the 
HSCT Program of Amaral Carvalho Foundation (ACF), in 
the city of Jahu, São Paulo State, Brazil from January to 
December 2014.
Population
Patients from all States of Brazil are referred to our 
center to undergo HSCT. One hundred and thirty patients 
were invited to participate in the study and signed the 
informed consent. Three patients were excluded due to 
death or relapse of the underlying disease before starting 
the revaccination protocol, and five patients due to lack 
of compliance with the study follow-up. Thus, 122 HSCT 
recipients were analyzed.
Revaccination Program
The revaccination program begins around the fourth 
month of transplantation and, generally, all patients return 
to their hometowns to start vaccines locally. Live attenuated 
vaccines are started only after the second year of HSCT in 
patients not receiving immunosuppressive drugs. Table 1 
shows the revaccination schedule proposed by the Amaral 
Carvalho Foundation HSCT center, and Table 2 shows the 
CRIE13 and the IDSA Guidelines schedule14.
Study design
Quantitative, non-randomized and single-center study, 
including two cohorts of patients: Group 1) patients who 
had already initiated the revaccination process; Group 2) 
patients who were close to start the program. Group 1 
consisted of 72 HSCT recipients (59%), at a median of 363 
days after HSCT (range 106-722), who had already started 
the revaccination program. After signing the informed 
consent, patients were questioned about the difficulties 
related to the revaccination program. Then, their vaccination 
cards were compared to the local protocol and designated as 
appropriate or not, according to the time after vaccination 
start. After this initial retrospective evaluation, patients 
from Group 1 were prospectively followed up until the 
Table 1 - HSCT revaccination schedule at Amaral Carvalho Foundation
Vaccines No of doses Dose interval (days) Comments
Pneumococcal conjugate (PCV-10) 3 30 ≤ 5 years old only
Pneumococcal conjugate (PCV-13)* 3 (all ages) 30 At private vaccination clinics
Pneumococcal polysaccharide 
vaccine(PPV-23)
1 - 30 days after the last dose of PCV
Tetanus, diphtheria (Td or Tdap) 3 30 Children ≥ 7 years old and adults
Tetanus, diphtheria, pertussis (TDP or TDaP) 3 30 < 7 years old
Haemophilus influenza conjugate (Hib) 3 30 -
Meningococcal conjugate (MCV) 2 60 -
Inactivated polio (IPV) 3 30 Also for household contact siblings
Recombinant hepatitis B (HBV) 3 0-30-180 2nd and 3rd doses after 30 and 180 days 
after the 1st dose, respectively
Hepatitis A vaccine (HAV) 2 180 -
Human papillomavirus (HPV) 3 0-60-180 2nd and 3rd doses after 60 and 180 days 
after the 1st dose, respectively 
Between 9 and 26 years old
Inactivated influenza (INF)** 1-2 30 Annually.
Measles-Mumps-Rubella (MMR)*** 1 -
Varicella (Varivax)*** 0 - Only considered in individual basis
Yellow fever (YFV)*** 1 - According to country recommendation
*PCV-13 preferred based on published data. Available only in private vaccination clinics. **Two doses from 6 months to < 9 years 
old; ***Live attenuated vaccines, only recommended after the 2nd year and without immunosuppression.
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end of their revaccination process. Group 2 consisted of 50 
HSCT recipients (41%) at a median of 138 days after HSCT 
(range 94-462), who were close to start the revaccination 
program. After a brief explanation, patients were referred 
to the vaccination centers. 
Live attenuated vaccines
Patients after the second year of HSCT were not 
included in the study due to logistical reasons; therefore, 
delays or problems regarding live attenuated vaccines were 
not analyzed. Except by measles vaccine, yellow fever (YF) 
and varicella (chickenpox) vaccines are recommended 
only in special circumstances. We followed the country 
recommendation for YF vaccination of patients living in risk 
areas. Varicella vaccine is only recommended in children 
in specific situations. For VZV seropositive adults, there 
is no proven benefit of the vaccine, as many of them have 
already developed herpes zoster up to the second year of 
HSCT, when vaccination is safe.
Definitions
According to our vaccination program, patients are 
expected to complete the vaccine schedule 8 months 
after starting revaccination, except by the live attenuated 
vaccines. By definition, those who did not complete the 
expected schedule were considered out of step. The main 
reasons for failures were grouped into the following 
categories: 1) related to patient compliance; 2) related to 
HSCT center modifications of previous recommendations; 
and 3) related to errors made by public vaccination centers.
Follow-up
Copies of the vaccine cards were taken at inclusion and 
regularly thereafter, to track the progress of revaccination. 
Patients were prospectively followed up by phone calls, 
emails, cell phones apps, or personally during medical 
appointments. Whenever a gap on the vaccination program 
was encountered or a difficulty was reported, personalized 
interventions and subsequent evaluations were performed. 
Interventions always focused on the needs of each patient, 
and a close contact with the vaccination centers was 
maintained through phone calls and orientation letters.
Ethical issues
The study was analyzed by the Ethics Committee of 
the Amaral Carvalho Foundation and is available at http://
aplicacao.saude.gov.br/plataformabrasil/login.jsf. Patients 
were informed about the risks and benefits of the research 
and signed the “Informed consent”, according to the 466/12 
resolution of the National Health Council.
Table 2 - Differences in CRIE and IDSA revaccination schedules proposed to HSCT recipients
Vaccines CRIE 2014 No of doses
IDSA Guidelines 2013 
No of doses
Pneumococcal conjugate (PCV-10) 3 (≤5 years-old only) 0
Pneumococcal conjugate (PCV-13) 0 3 (all ages)
Pneumococcal polysaccharide vaccine(PPV-23) 2 1
Tetanus, diphtheria (Td) 3 3
Acellular (DTPa) (<7 yr) 3 3
Haemophilus influenza conjugate (Hib) 3 3
Meningococcal C conjugate (MCV) 1 2
Inactivated polio (IPV) 3 3
Recombinant hepatitis B (HBV) 3 3
Hepatitis A vaccine (HAV) 2 Idem to general population
Human papillomavirus (HPV) 0 3 (female aged 11-26 yr and HPV4 vaccine 
for males aged 11-26 yr)
Inactivated influenza (INF)* 1-2 (annually) 1-2 (annually)
Measles-Mumps-Rubella (MMR)** 2 2
Varicella (Varivax)** 2 2
Yellow fever (YFV)** 1 Idem to general population
*Two doses if < 9 years of age; **Live vaccines, only recommended after the 2nd year and without immunosuppression
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Statistical analysis
Continuous variables were expressed as medians. 
Comparison of qualitative or categorical variables was 
analyzed using the chi-square test. Logistic regression 
analysis was performed to determine the variables associated 
with delays in the revaccination program (software SPSS 
version 19.0).
RESULTS
Characteristics of the patients analyzed in the study are 
shown in Table 3. 
The beginning of the vaccination program occurred 
at a median of 163 days (ranging from 69 to 489 
days) in group 1 and 166 days (114 to 466) in group 2 
(p=0.35).
Eleven from 72 patients (15.3%) in Group 1 and 
11 from 50 in Group 2 (22%) presented pitfalls related 
to patient compliance (p=0.34). Forty-one patients in 
Group 1 (56.9%), and 24 in Group 2 (48%) presented 
pitfalls related to HSCT center modifications of previous 
recommendations (p=0.33); and 41 (56.9%) and 25 (50%) 
patients in Groups 1 and 2, respectively, had pitfalls due 
to errors made by the vaccination center (p=0.44). In 
total, 105 HSCT recipients (86%) presented at least one 
problem, 63 (87.5%) in Group 1 and 42 (84%) in Group 
2 (p=0.58) (Table 4).
Table 3 - Characteristics of HSCT recipients (N=122) 
Group 1 
N (%)
Group 2 
N (%)
p-value
No of patients (%) 72 (59) 50 (41)
Median age 36 (3 – 72) 27 (1 – 66) 0.15
Sex
       Female 26 (36.1) 22 (44) 0.38
       Male 46 (63.9) 28 (56)
Region
       Midwest 2 (2.8) 3 (6) 0.18
       Northeast 18 (25) 13 (26)
       North 2 (2.8) 6 (12)
       Southeast 43 (59.7) 26 (52)
       South 7 (9.7) 2 (4)
Underlying disease
       ALL 18 (25) 13 (26) 0.39
       AML 19 (26) 10 (20)
       CML 10 (14) 2 (4)
       MM 5 (7) 10 (20)
       Other 20 (28) 15 (30)
HSCT type
       Allogeneic RD/UD 52/11 (72/15) 24/12 (48/24) 0.04
       Autologous 9 (13) 14 (28)
Conditioning regimen
       Myeloablative/Non-M 50/18 (75/25) 45/5 (90/10) 0.03
ATG use
       Yes/No 6/66 (8.3/91.7) 38/12 (24/76) 0.01
Stem cell source
       Bone marrow 38 (52.8) 24 (48) 0.39
       Cord blood 2 (2.8) 0 (0)
       PBSC 32 (44.4) 26 (52)
RD=related donor; UD=unrelated donor; M=myeloablative
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Delays in one or more vaccines were frequently 
observed (86/105, 81.9%). Table 5 presents the frequency 
of vaccine delays. 
Univariate analysis showed that type of transplant, 
mye loab l a t ive  cond i t i on ing ,  GVHD,  u se  o f 
immunosuppressive drugs, clinical complications, adverse 
reactions and lack of patient compliance did not contribute 
significantly to vaccine delays. The non-authorization of 
vaccines by the vaccination center was the only variable that 
had a significant impact on the delay of the revaccination 
program, as shown in Table 6.
Concerning to the pneumococcal conjugate vaccine, 19 
patients in group 1 (26.4%) and 4 (8%) in group 2 (p=0.01) 
did not get the vaccine because the Brazilian Ministry of 
Healthy does not allow its use in subjects older than 5 years 
Table 4 - Problems in the revaccination program according to category and patient group (N=105)
Category Problems Group 1 (N=63) N (%)
Group 2 (N=42) 
N (%) p-value
Patient compliance
Lack of commitment 6 (9.5) 2 (4.8) 0.36
Difficulty to contact 6 (9.5) 4 (9.8) 0.94
Misunderstanding of the orientation 2 (3.2) 5 (11.9) 0.07
HSCT center
Delay without justification 6 (9.5) 3 (7.1) 0.66
Delay due to complications 8 (12.7) 7 (16.7) 0.56
Delay due to GVHD 21 (33.3) 5 (11.9) 0.01
Delay due to IS without GVHD 7 (18.9) 6 (33.3) 0.23
Vaccination center
Lack of trained team/poor organization* 28 (44.4) 18 (42.9) 0.87
Vaccine was properly indicated but not autho-
rized by the vaccination center 10 (15.9) 3 (7.1) 0.18
Patients’ perception of lack of commitment from 
the health personnel 11 (17.5) 10 (23.8) 0.42
Administration of a not-indicated vaccine that 
could represent a risk for the patient 6 (9.5) 1 (2.4) 0.15
*Various: use of vaccines that should not be applied; team unaware of the procedure to get specific vaccines; vaccine denied due 
to fear; vaccination denied because the patient “had already been vaccinated in childhood”; inadequate completion of the vac-
cination cards.
Table 5 - Vaccine delays according to patient group (N=86)
Vaccine
Group 1 
(N=57)
Group 2 
(N=29) p-value
N (%) N (%)
Hib 29 (50.9) 21 (72.4) 0.05
MCV 32 (56.1) 3 (10.3) <0.001
PCV10 31 (54.4) 9 (31) 0.04
HAV 18 (31.6) 2 (6.9) 0.01
PPV23 16 (28.1) 1 (3.4) 0.007
IPV 11 (19.3) 3 (10.3) 0.28
dT/DTP 10 (17.5) 3 (10.3) 0.37
HBV 6 (10.5) 3 (10.3) 0.97
Table 6 - Variables associated with vaccine delays (n=122)
Variable
Vaccine delay
p-value
Yes (%) No (%)
Type of HSCT
Allogeneic 72 (72.7) 27 (27.3) 0.26
Autologous 14 (60.9) 09 (39)
Mieloablative conditioning
Yes 56 (74.7) 19 (25.3) 0.44
No 16 (66.7) 08 (33.3)
Graft versus host disease
Yes 24 (77.4) 07 (22.6) 0.32
No 62 (68.1) 29 (31.9)
Immunosuppressive drugs
Yes 11 (68.8) 05 (31.3) 0.87
No 75 (70.8) 31 (29.2)
Clinical intercurrences
Yes 13 (65) 07 (35) 0.55
No 73 (71.6) 29 (28.4)
Adverse reactions
Yes 05 (50) 05 (50) 0.13
No 81 (72.3) 31 (27.7)
Lack of patient compliance
Yes 08 (100) 0 (0) 0.06
No 78 (68.4) 36 (31.6)
Vaccine not authorized 
Yes 13 (100) 0 (0) 0.01
No 73 (67) 36 (33)
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according to the product label. In two patients, one in group 
1 (1.4%) and one in group 2 (2%), the vaccination center 
considered that the PPV23 was enough and did not authorize 
the PCV (p=0.79). Only four (5.6%) and one (2%) patients 
in groups 1 and 2, respectively, were given a justification 
letter on the non-vaccination for PCV by the vaccination 
center (p=0.33). The refusal of pneumococcal vaccine was 
not uniform, as some centers applied the vaccine without 
questioning.
Advisory intervention was necessary in 46 episodes in 
Group 1 (63.9%) and 23 in Group 2 (46%) (p=0.05). Results 
of the intervention did not differ significantly among groups 
and were partially succesful in 30 (65.2%) of Group 1, with 
total resolution observed in 17 of them (37%). Similarly, 
partial success was achieved in 18 patients (78.3%) from 
Group 2, with total resolution of the problems in 9 of them 
(39%).
DISCUSSION
Our study describes the pitfalls encountered by HSCT 
recipients who performed the revaccination schedule at 
their hometowns.
Current revaccination schedules include numerous 
vaccines, with different number and specific intervals 
between doses that should be managed to optimize the 
frequency of patient visits to the vaccination center, 
reflecting the program complexity. In addition, clinical 
complications may occur during patient’s follow-up and a 
trained team of health professionals is essential to evaluate 
the real need of vaccine postponing. Any rupture in this 
chain results in delay in the revaccination program.
Indeed, the main difficulty encountered in our study 
was vaccination delays (81.9%). In general, lack of patient 
compliance contributed less to revaccination pitfalls 
(around 20%) than the issues related to the HSCT unit or 
the vaccination centers (more than 50%).
Concerning the HSCT center, a trained nurse proved 
to be an ideal supervisor for the revaccination program 
and, along with the transplant infectious disease (TID) 
doctor, may organize the program and disseminate updated 
information about vaccine protocols among the HSCT team. 
Tracking program progress can be made through vaccination 
cards, phone calls or text messages, Facebook notes, among 
other initiatives as suggested by some authors15. 
Constant monitoring is the key to a successful 
revaccination program. Our study showed that patients who 
were prospectively monitored by a trained nurse needed 
significantly less intervention than the group who had 
already started their revaccination process (46% and 64%, 
respectively, p=0.05). Advisory intervention by the nurse 
and the TID doctor resulted in partial or total resolution of 
the problems, in around 65% and 37%, respectively.
GVHD is a frequent reason reported by the HSCT team 
to postpone vaccines. In 105 patients who had problems in 
their vaccination schedule, GVHD delayed vaccination in 
24.7% of them. Group 1 accounted with the majority of the 
delays (33%) probably because those patients had already 
started the vaccine program before inclusion in the study. 
The advisory supervision by the nurse conducting the study 
significantly decreased the delays due to GVHD in Group 
2, since the patients were followed from the beginning of 
the protocol (Table 4, p=0.01).
Postponing vaccination due to GVHD seems unjustified, 
as guidelines do not recommend, except for live vaccines2,9,10. 
In addition, there is no evidence of exacerbation of chronic 
GVHD after use of inactivated vaccines16. Nevertheless, a 
survey conducted by Hudspeth et al.9 demonstrated that 
most of the surveyed centers (59%) delayed not only live 
virus vaccines, but also inactivated vaccines in the presence 
of GVHD9. Another study evaluating the vaccination 
practices for patients with GVHD showed that 30% of the 
transplantation centers delayed all vaccines, 30% delayed 
only the live vaccines and 39% delayed all vaccines except 
for influenza and/or pneumococcal vaccine12.
It is known that GVHD and its treatment may decrease 
vaccine responses to T-cell and antibodies2,3,10,17,18 and that 
is the main excuse used by the HSCT team to postpone 
vaccination. A more recent communication from the 
International Consensus Conference on Clinical Practice in 
chronic GVHD proposed the postponement of vaccinations 
for up to 3 months in adult patients, if they are receiving 
three or more immunosuppressive agents for the treatment 
of GVHD19. However, some of these patients may respond 
to vaccines. As the recommended vaccines (except for the 
live ones) are safe in the GVHD scenario, some authors 
recommend to measure specific antibody levels before 
and after vaccination to evaluate protection and the need 
for booster doses2,9.
Some authors have found that allogeneic HSCT 
recipients have frequent delays in the revaccination program 
due to recurrent clinical complications during follow-up12. 
In our study, the type of HSCT was not associated with 
vaccine delays. Allogeneic HSCT recipients presented 
similar rates of vaccine delay (72%), in comparison to 
autologous (61%, p=0.26). Other authors observed that 
patients undergoing autologous or allogeneic transplants 
presented different problems causing missed and/or delayed 
vaccination, although no statistical comparison was made 
between groups15.
A variety of immunization protocols have been 
proposed. In 1995, a survey developed among HSCT 
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centers demonstrated that vaccines were improperly used, 
protocols were very different among centers and just few 
centers used multiple vaccine doses9. Thus, it is clear that 
the acceptance of the recommended revaccination program 
varies according to the center and, in some of them, up to 
48% of the patients have no appropriate reason to be out 
of step with their vaccination schedule15. Fortunately, the 
vaccination protocol seems to be accepted by the HSCT 
team at Amaral Carvalho Foundation. Only a small number 
of patients in both groups had vaccine delays without 
reason, 6 in group 1 (14.3%) and 5 in group 2 (18.5%, 
p=0.63).
Concerning to the vaccination centers, the most 
frequent problem found was the lack of a properly trained 
team and/or poor organization. Health personnel working 
at the Basic Health Units do not seek guidance from the 
CRIE, as how to obtain special vaccines and specific 
immunoglobulin, or how to manage adverse situations. 
CRIEs should be the first to be consulted in these cases. 
In our study, more than 40% of the problems related to the 
vaccination center fell in this category. Moreover, 9.5% of 
the patients in group 1 and 2.4% in group 2 received live 
vaccines, which were incorrectly indicated considering the 
post-transplantation period. Health professionals working 
in this scenario should have adequate training and frequent 
expert supervision to clarify doubts and reduce errors that 
can be life threatening.
Unfortunately, the cost effectiveness of the immunization 
program provided by the Brazilian Ministry of Health may 
result disappointing if properly trained health professionals 
were not available. Other authors analyzing children’s 
vaccination records and the health service at Botucatu 
city, São Paulo State, Brazil, observed that approximately 
30% of the studied population were not informed about the 
administered vaccine, the next vaccines to be scheduled, the 
possibility of adverse reactions, or they received inadequate 
information. The lack of orientation was the main cause of 
delayed vaccines, identified in 60% of the cases20.
In our study, the highest proportion of delay was found 
with MCV in patients from group 1 and with Hib in patients 
from group 2. The vaccine against meningitis C has been 
recently incorporated to the CRIE’s vaccination schedule 
as recommended to HSCT recipients, justifying the delay 
in 32 (56.1%) of the patients in Group 113. In previous 
international guidelines, meningococcal vaccine was 
just recommended if indicated2,4. As patients in group 2 
initiated the process using the updated protocol, only a few 
delays in MCV vaccine were observed in this group. The 
delay in carrying out Hib vaccine in patients from group 
2 was related to an interruption in vaccine distribution by 
the National Laboratory, Bio-Manguinhos/Fiocruz, since 
November 2014 (personal communication by Carla Magda 
Allan Santos Domingues), while most of the patients in 
group 1 had already completed this stage of the protocol.
Although less frequent than the delays observed with 
MCV and Hib, the pneumococcal vaccines deserve special 
comments. The first licensed conjugate pneumococcal 
vaccine was PCV7 (Prevnar, Pfizer, Inc. New York), which 
offers protection against serotypes 4, 6B, 9V, 14, 18C, 19F 
and 23F21. This vaccine was proven to be immunogenic 
and safe in both child and adult HSCT recipients22,23. 
The 10-valent pneumococcal vaccine (Synflorix, GSK, 
Brentford, UK) was also licensed in Europe, and uses 
different carrier proteins compared to PCV7 and offers 
seroprotection against three additional serotypes (1, 5, and 
7F). The PCV10 was never tested in transplant patients24.
In 2010, the new 13-valent pneumococcal vaccine 
(Prevnar 13, Pfizer, Inc., New York), was already approved 
and being tested in HSCT recipients. At that moment, the 
recommendation has been to use PCV13, if the 7-valent 
vaccine was no longer available24. The study evaluating 
PCV13 in HSCT recipients has been recently published 
and confirmed the safety and effectiveness of the vaccine11.
In Brazil, the PCV10 was introduced in the national 
immunization program in 2010 for children younger than 
2 years old14, and then included in the vaccination schedule 
for immunocompromised patients up to 5 years (off-label), 
as a substitute for PCV7. The PCV13 is not offered by the 
Brazilian Ministry of Health, and is only available in private 
vaccination clinics.
In our study, the delay observed in pneumococcal 
vaccination was due to the refusal by the vaccination 
center to vaccinate adult patients. The Brazilian Ministry 
of Health considers the PCV10 in adults “off-label” as the 
product label indicates its use in children up to 5 years25. 
Unfortunately, since the PCV7 is no longer available, and 
the PCV13 is currently not included in the national program, 
an immediate change in this scenario seems unlikely and 
adult HSCT recipients can only receive the PPV23.
However, some studies have shown that the best 
response to pneumococcal vaccine is observed when 
conjugate vaccines are used before the polysaccharide 
vaccine. de Roux et al.22 compared the immunogenicity 
and safety of PCV7 with PPV in adults immunized at 
study entry and receiving a second dose of PCV7 or PPV 
after one year. The authors demonstrated that the highest 
responses occurred in the group receiving 2 doses of the 
conjugate vaccine, and the lowest responses were observed 
in the PPV/PCV7 group.
Cordonnier et al.23 used the PCV7 vaccine in HSCT 
recipients with a median age of 37 years old (range 7 to 
59). Response to PCV7 given 3 months after transplantation 
Silva et al.
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was not inferior to the late start at 9 months of HSCT (79% 
in early and 82% in late vaccination). They also studied 
the effects of PPV23 vaccination after PCV7 in HSCT 
recipients, and showed that among patients who did not 
have a response after three doses of PCV7, 41% responded 
to the PCV7 antigens after receiving a dose of PPV23. 
Therefore, PPV23 may not only confer protection to 16 
extra serotypes, but may also boost the response to PCV7 
serotypes. Thus, authors recommended the use of 3 doses 
of PCV7 at monthly intervals, starting 3 months after HSCT 
transplantation, followed by one dose of PPV23.
Recently, the same authors using 4 doses of PCV13 (3 
doses with one month interval and a 4th dose after 6 months) 
in pediatric and adult allogeneic recipients, identified an 
increase in antibody levels after 3 doses across all PCV 13 
serotypes, with a significant decline in the next six months 
but, a new increase after the 4th dose. The use of PPV23 one 
month after the fourth dose usually maintained stable the 
antibody levels, even though an increase in systemic and 
local adverse reactions may occur11.
Finally, the number of doses may also play an important 
role in vaccination delays. In our study, the vaccine against 
influenza virus was the only vaccine with no delay. Besides 
being a single dose vaccine, our institution develops a solid 
annual program to control respiratory virus transmission, 
targeting patients, caregivers and health professionals, 
which includes influenza vaccine campaign, may explain 
this result26.
Nelson et al. 27 evaluated the proper fulfillment of some 
vaccines that require multiple doses (varicella, hepatitis 
A, and hepatitis B vaccine). Completion rates of all doses 
were higher for hepatitis B vaccine (55%-65% in most age 
groups) within a year, whereas compliance with hepatitis 
A and varicella vaccines was lower (40%-50% for most 
age groups). The authors observed that compliance with 
multiple doses was low, particularly among adolescents, 
young adults and low socioeconomic level individuals.
The present study demonstrated that no matter the 
problem identified, the main consequence would be 
the delay in the revaccination program. The refusal in 
administrating the vaccine by the vaccination center was 
identified as the major reason for delays. The conjugate 
pneumococcal vaccine should be urgently made available 
to adult HSCT recipients since there is scientific evidence 
of its safety and effectiveness.
Vaccination guidelines have been developed and 
updated; however, the Brazilian revaccination program 
needs to be adjusted and the Basic Health Units need to 
improve relationship with the CRIE, because many HSCT 
recipients remain unvaccinated, are vaccinated late, or 
undergo an incomplete vaccination schedule.
All efforts should be made to assure that HSCT 
recipients have access to a safe and complete revaccination 
program. Our study showed that tailored follow-up 
performed by nurses and TID doctors helped to overcome 
the difficulties faced in this process.
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